7 results
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
stratification algorithm ... thrombosis; PE = pulmonary ... #Anticoagulation ... #Management #Hematology ... #Oncology
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
Treatment algorithm ... Suggested treatment algorithm ... #Anticoagulation ... #Management #Hematology ... #Oncology
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Differentiation Syndrome ... Imaging: CXR- pulmonary ... Differentiation #Syndrome ... APML #diagnosis #management ... #hematology #oncology
Clotmaster Consensus 2019: Duration of Therapy for Venous Thromboembolic Disease
 • Superficial Venous Thrombosis
 • Upper
Spontaneous • Calf ... post-thrombotic syndrome ... Bloodman #VTE #anticoagulation ... #duration #management ... #DVT #hematology
Amiodarone Induced Lung Toxicity Summary

Who?
• 5% of patients
• Dose ≥ 400 mg per day

How?  Possible
Amiodarone Induced Lung ... Direct cytotoxic lung ... • Amiodarone half ... respiratory distress syndrome ... #diagnosis #management
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
murmur 3/6) - Pulmonary ... event, follow ACC algorithm ... Anticoagulation ... unless prior heart/lung ... medical and surgical management
Essential Thrombocythemia (ET)
ET is a chronic myeloproliferative neoplasm. Most cases are related to mutations that affect
JAK2, CALR-calreticulin ... • Treatment algorithms ... Hydroxyurea + anticoagulation ... #diagnosis #management ... #hematology